Post by BackTable Tumor Board

With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this collaboration episode with BackTable Urology, Alan Tan, MD is joined by Emmanuel S. Antonarakis, M.D. and Dr. Rana McKay to break down the latest evidence on PARP inhibitor combination therapy, share key takeaways from recent studies like PROpel, MAGNITUDE, TALAPRO-2, and AMPLITUDE, and reflect on insights from #APCCC2026. Utilize the Backtable App to access the full episode and more: https://lnkd.in/g6RHtKrT This podcast is supported by an educational grant from Pfizer. #URO314 #TB71 #Urology #UrologyResidency #ProstateCancer #MedEd